ID   H1650-ER1
AC   CVCL_4V01
DR   cancercelllines; CVCL_4V01
DR   Wikidata; Q54871955
RX   PubMed=22433462;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib.
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-2A>G (IVS6-2A>G); ClinVar=VCV000458555; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C2923; Minimally invasive lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1483 ! NCI-H1650
SX   Male
AG   27Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 12
//
RX   PubMed=22433462; DOI=10.1186/1471-2407-12-95;
RA   Ghosh G., Lian X.-J., Kron S.J., Palecek S.P.;
RT   "Properties of resistant cells generated from lung cancer cell lines
RT   treated with EGFR inhibitors.";
RL   BMC Cancer 12:95.1-95.14(2012).
//